In the cutting-edge field of biological research, the development of bispecific antibodies has emerged as a revolutionary approach to cancer therapy. This innovative technology features unique design and mechanisms of action, holding significant promise in the therapeutics of various malignancies. Leveraging the ImmunBridge™ platform, our company stands at the forefront of bispecific antibody development, driving advancements in redefining the landscape of cancer intervention.
-
PBID: 0230001500000277
-
2 Les gens qui ont lié ça
-
0 Articles
-
0 Photos
-
0 Vidéos
-
Aperçu
-
Science and Technology
Rechercher
English
Arabic
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek
Mises à jour récentes
Aucune donnée à afficher